Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-27T15:36:23.739Z Has data issue: false hasContentIssue false
  • English
  • Français

Patterns of clozapine use, misuse and disuse in a mental health area in southern Spain

Published online by Cambridge University Press:  01 September 2022

L.I. Muñoz-Manchado ,
J.M. Mongil-Sanjuan ,
J.M. Pascual Paño ,
C. Rodríguez-Gómez ,
R. Torrecilla-Olavarrieta ,
J.I. Pérez-Revuelta ,
F. González-Saiz  and
J.M. Villagrán-Moreno
L.I. Muñoz-Manchado*
Affiliation:
UGC North of Cadiz, Mental Health Inpatient Unit, General Hospital, Jerez de la Frontera, Spain
J.M. Mongil-Sanjuan
Affiliation:
UGC North of Cadiz, Mental Health Inpatient Unit, General Hospital, Jerez de la Frontera, Spain
J.M. Pascual Paño
Affiliation:
UGC North of Cadiz, Mental Health Inpatient Unit, General Hospital, Jerez de la Frontera, Spain
C. Rodríguez-Gómez
Affiliation:
UGC North of Cadiz, Mental Health Inpatient Unit, General Hospital, Jerez de la Frontera, Spain
R. Torrecilla-Olavarrieta
Affiliation:
UGC North of Cadiz, Mental Health Inpatient Unit, General Hospital, Jerez de la Frontera, Spain
J.I. Pérez-Revuelta
Affiliation:
UGC North of Cadiz, Mental Health Inpatient Unit, General Hospital, Jerez de la Frontera, Spain
F. González-Saiz
Affiliation:
UGC North of Cadiz, Mental Health Inpatient Unit, General Hospital, Jerez de la Frontera, Spain
J.M. Villagrán-Moreno
Affiliation:
UGC North of Cadiz, Mental Health Inpatient Unit, General Hospital, Jerez De La Frontera, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Evidence supports clozapine as the best treatment in terms of efficacy, effectiveness and well-being, and as the gold standard in treatment-resistant psychotic disorders. Clozapine remains still underused, suffering initiation delays from 1.1 to 9.7 years. Furthermore, there is a scarcity of data about patterns of use, showing high variability worldwide (0.6-189.2/100. 000 inhabitants).

Objectives

The main objective of this work is to carry out an analysis of the use of clozapine in our mental health catchment area. Thus, off-label use, the percentage of patients with clozapine depending on diagnosis, age and sex, and its use in mono and polytherapy are established. Besides, dosage and time between the first contact and the start of treatment with clozapine are recorded.

Methods

A descriptive study has been developed on the patients with clozapine who consulted in the catchment area of the Jerez Mental Health Service between 2018 and 2019. Data were extracted from medical records.

Results

From our population of 456.752 inhabitants, 449 patients received clozapine. 278 (61.9%) had a schizophrenia diagnosis; 33 (7.3%) delusional disorder and 34 (7,6%) schizoaffective disorder. The off-label use of clozapine was 19,1 %. The average mean dose used was 246,2 mg/day and 59% of the patients on clozapine were on polytherapy. Only 14,7% of these patients had a previous trial with clozapine on monotherapy.

Conclusions

Rates of polytherapy, previous trials of clozapine monotherapy, off label use, rates of discontinuation and other variables are to be considered to precisely map the adequate use of clozapine in clinical settings.

Disclosure

No significant relationships.

Keywords

clozapinePatterns of usePSYCHOTIC DISORDERS
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S711 - S712
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.